Survivin-derived peptides presented on HLA class I (Survivin-HLA-I)

Survivin-derived peptides presented on HLA class I molecules serve as highly specific tumor-associated antigens (TAAs) for cancer immunotherapy. Survivin, also known as Baculoviral IAP repeat-containing protein 5 (BIRC5), is a unique protein that functions as an inhibitor of apoptosis and a regulator of cell division, showing massive overexpression in nearly all human malignancies while remaining nearly undetectable in differentiated normal tissues [1, 2]. The presentation of its proteolytic fragments on the cell surface via the Human Leukocyte Antigen (HLA) class I pathway allows the immune system to identify and target malignant cells [3]. Therapeutic interventions, such as the SurVaxM vaccine or TCR-engineered T cells, are designed to recognize these specific peptide-HLA complexes to trigger a cytotoxic T-cell response [4, 5]. This target is particularly attractive because survivin is essential for cancer cell survival, potentially limiting the emergence of antigen-loss variants [6]. However, challenges include the heterogeneity of HLA alleles across patient populations and the potential for immune evasion through the downregulation of the antigen presentation machinery [7].

Other names

BIRC5-derived peptidesSurvivin-MHC class I complexSurvivin-HLA complexSurvivin epitopesSurvivin-derived MHC-I restricted peptides

Induction of peptide-specific CD8+ T-lymphocyte responses that recognize and lyse tumor cells presenting survivin fragments on HLA class I molecules.